Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211068
Status:
COMPLETED
Last Update Posted:
2013-04-30
First Post:
2005-09-13
Brief Title:
A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
Sponsor:
Johnson Johnson Pharmaceutical Research Development LLC
Organization:
Johnson Johnson Pharmaceutical Research Development LLC
Study Overview
Official Title:
Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to collect historical occurrences of risk factors that are potentially associated with the development of anti-erythropoietin EPO antibody positive pure red cell aplasia PRCA in participants with chronic kidney disease who have been recently treated with epoetin alfa EPREX
Detailed Description:
This is a multicenter study conducted at multiple sites case-control study that compare individuals with a disease or condition cases to a group of individuals without the disease or condition controls to determine the possible factor which increased disease incidence retrospective a study in which the participants are identified and then followed backward as time passes study Retrospective risk factor data will be collected for control participants matched to the subset of participants in Protocol EPO-IMU-301 identified as having chronic kidney disease and anti-EPO antibody positive PRCA that began while the participant was receiving treatment with EPREX index participants For each index participant up to 4 matched non-PRCA control participants with chronic kidney disease will be enrolled in this study Approximately 600 control participants will be enrolled in this study Control participants will be selected from the same site as the index participant and the data will be collected from the date closest to the reference date loss of efficacy drop in hemoglobin of greater than 2 gdLmonth was first seen that the control participant satisfies all study inclusion and exclusion criteria The optional pharmacogenomic part testing for polymorphisms and haploid types of the erythropoietin gene will be recorded for the control participants who will sign the pharmacogenomics part of the study No drug administration or treatment will be mandated by this study Safety evaluation will include assessment of adverse events
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EPO-IMU-403 | OTHER | Johnson Johnson Pharmaceutical Research and Development LLC | None |